EMEXED (Emcure Pharmaceuticals Pty Ltd)
Product name
EMEXED
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
254 working days (255)
Active ingredients
pemetrexed (as disodium)
Registration type
New generic medicine
Indication
EMEXED (powder for injection) is indicated for the treatment of:
Malignant Pleural Mesothelioma
PEMETREXED, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.
Non-Small Cell lung Cancer
PEMETREXED in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
PEMETREXED as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.